Commercial vaccines do not confer protection against two genetic strains of *Piscirickettsia salmonis*, LF-89-like and EM-90-like, in Atlantic salmon.

Carolina Figueroa¹, Débora Torrealba¹, Byron Morales-Lange², Luis Mercado², Brian Dixon³, Pablo Conejeros⁴, Gabriela Silva⁵, Carlos Soto⁵, José A. Gallardo^{1*}

¹Laboratorio de Genética y Genómica Aplicada, Escuela de Ciencias del Mar, Pontificia Universidad Católica de Valparaíso, Valparaíso, Chile

²Grupo de Marcadores Inmunológicos en Organismos Acuáticos, Instituto de Biología, Pontificia Universidad Católica de Valparaíso, Valparaíso, Chile

³Centro de Investigación y Gestión de Recursos Naturales (CIGREN), Instituto de Biología, Facultad de Ciencias, Universidad de Valparaíso, Valparaíso, Chile

⁴Department of Biology, Faculty of Science, University of Waterloo, Waterloo, Ontario, Canada

⁵Salmones Camanchaca, Diego Portales 2000, Puerto Montt, Chile

* Correspondence:

José A. Gallardo

jose.gallardo@pucv.cl

Keywords: pentavalent vaccine, live attenuated vaccine, *Piscirickettsiosis*, *Salmo salar*, cohabitation, sea lice, vaccine efficacy.

Abstract

In Atlantic salmon, vaccines have failed to control and prevent *Piscirickettsiosis*, for reasons that remain elusive. In this study, we report the efficacy of a commercial vaccine developed with the *Piscirickettsia salmonis* isolate AL100005 against other two isolates which are considered highly and ubiquitously prevalent in Chile: LF-89-like and EM-90-like. Two cohabitation trials were performed to mimic real-life conditions and vaccine performance: 1) post smolt fish were challenged with a single infection of LF-89-like, 2) adults were coinfecting with EM-90-like and a low coinfection of sea lice. In the first trial, the vaccine delayed smolt mortalities by two days; however, unvaccinated and vaccinated fish did not show significant differences in survival (unvaccinated: 60.3%, vaccinated: 56.7%; $p = 0.28$). In the second trial, mortality started three days later for vaccinated fish than unvaccinated fish. However, unvaccinated and vaccinated fish did not show significant differences in survival (unvaccinated: 64.6%, vaccinated: 60.2%, $p = 0.58$). Thus, we found no evidence that the evaluated vaccines confer effective protection against of LF-89-like or EM-90-like with estimated relative survival proportions (RPSs) of -9% and -12%, respectively. More studies are necessary to evaluate whether pathogen heterogeneity is a key determinant of the vaccine efficacy against *P. salmonis*.

1 Introduction

Piscirickettsia salmonis is a major concern for the Chilean salmon industry, causing economic losses of USD 700 million per year (Maisey et al., 2017; Rozas and Enriquez, 2014). Piscirickettsiosis is an exceptionally contagious disease, with a high prevalence in clustered regions in Chile, causing mortalities of over 50% of production (Jakob et al., 2014; Leal and Woywood, 2007). While Chile, the second-largest global producer of salmon, is by far the most affected country by this disease, it also affects the other main salmon producing countries, namely Norway, Canada and Scotland (Brocklebank et al., 1993; Grant et al., 1996; Olsen et al., 1997; SERNAPESCA, 2017).

Vaccination has been widely used as a control strategy to prevent Piscirickettsiosis (Happold et al., 2020), but unfortunately, all vaccines developed in the last 20 years have failed to protect Atlantic salmon against *P. salmonis* (Maisey et al., 2017). Some intrinsic and extrinsic factors that may explain why commercial vaccines present reduced protection against *P. salmonis* are 1) coinfection with sea lice, which were able to override the protective effects of vaccines (Figueroa et al., 2017; Figueroa et al., 2020 accepted); 2) host genetic variation, partially protecting some hosts while leaving others unprotected (Figueroa et al., 2017; Figueroa et al., 2020 accepted); and 3) ineffectiveness in stimulating cellular immunity, which is a key element to protecting against *P. salmonis* because this bacteria can survive inside the host cells. Likewise, other underlying causes may lead to low vaccine efficacy, such as the pathogen's genetic variation.

Since *Piscirickettsia* outbreaks in Chile are caused by a minimum of two different genetic strains, it has been suggested that this heterogeneity should be considered in vaccine development (Nourdin-Galindo et al., 2017; Otterlei et al., 2016). The reported efficacy of a commercial vaccine would not hold in the field when testing against bacterial strains with low virulence and/or a reduced prevalence in the field. In Chile, two strains—called LF-89-like and EM-90-like—are considered highly and ubiquitously prevalent (Saavedra et al., 2017). These strains show distinct laboratory growth conditions (Saavedra et al., 2017) and major differences in virulence-associated secretion systems and transcriptional units (Millar et al., 2018), resulting in different infective levels (Bohle et al., 2014). For example, it has been shown that EM-90-like isolates are more aggressive than the LF-89-like isolates, inducing higher cumulative mortalities (EM-90 = 95%; LF89 = 82%) and a shorter time to death (EM-90 = 42 days; LF89 = 46 days) in non-vaccinated post-smolt when evaluated by a cohabitation challenge (Rozas-Serri et al., 2017; Rozas-Serri et al., 2018). Contrary to the hypothesis of heterogeneity, an experimental vaccine developed with an isolate of EM-90 failed to protect against the same isolate (Cardella and Eimers, 1990; Meza et al., 2019).

In this study, we tested the efficacy of a commercial vaccine developed with the *P. salmonis* isolate AL100005 against the two most prevalent Chilean strains of *Piscirickettsia*, LF-89-like and EM-90-like. The challenges were carried out with Atlantic salmon (*Salmo salar*) and by cohabitation with fish that successfully adapted to saline conditions in order to best imitate the natural conditions of bacterial infection. In the first trial, LF-89-like was evaluated with post-smolt fish with a single infection of *P. salmonis*, while in the second trial, EM-90-like was evaluated with adult fish in a challenge that included a very low coinfection with the sea louse *C. rogercresseyi*, again to better emulate field conditions.

2 Materials and methods

Ethics Statement. This work was carried out under the guidance for the care and use of experimental animals of the Canadian Council on Animal Care. The protocol was approved by the Bioethics Committee of the Pontificia Universidad Católica de Valparaíso and the Comisión Nacional de

Investigación Científica y Tecnológica de Chile (FONDECYT N° 1140772). Animals were fed daily *ad libitum* with a commercial diet. To reduce stress during handling, vaccination was performed on fish that were sedated with AQUI-S (50% Isoeugenol, 17 mL/100 L water). Euthanasia was performed using an overdose of anesthesia.

Commercial vaccine: The commercial vaccine, hereafter “the vaccine”, used in this study was a pentavalent vaccine with antigens against *P. salmonis*, *Vibrio ordalii*, *Aeromonas salmonicida*, IPNV (Infectious Pancreatic Necrosis Virus) and ISAV (Infectious Salmon Anemia Virus). This vaccine is the most used (3821/8884 or 43 % of vaccination events in the freshwater phase of production) by Chilean farmers, as was reported by (Happold et al., 2020) The active principle of this vaccine to prevent Piscirickettsiosis is a inactivated vaccine of *P. salmonis* AL 10005 strain.

Challenge with LF-89-like (Trial 1). A total of 4983 individually pit-tagged smolt fish were provided in 2017 by the Salmones Camanchaca Company. Fish were transferred to the experimental station of the Neosalmon Company for the evaluation of the vaccine efficacy using a cohabitation challenge (Table 1). In total, 1223 of the fish had been previously immunized with the vaccine using the normal production schedule and were used as vaccinated fish (342 ± 55 g), 861 had been previously injected with Phosphate-Buffered Saline (PBS) and were used as unvaccinated fish (314 ± 61 g), while the remaining fish were used as Trojan shedders (152 ± 38 g).

Vaccinated and unvaccinated fish were distributed in four tanks: two tanks of 15 m³ for the cohabitation challenges and two tanks of 5 m³ for the control without infection. All fish were acclimatized to the experimental conditions (salinity of 32‰ and a temperature of 15 ± 1 °C) and tanks for at least 15 days prior to the challenge. Further, a health check by RT-PCR was performed to verify that the fish were free of viral (ISAV and IPNV) and bacterial pathogens (*Vibrio* sp., *Flavobacterium* sp., *P. salmonis*, and *Renibacterium salmoninarum*). The cohabitation tanks were challenged by adding Trojan shedders (table 1) which had been previously anesthetized with AQUI-S and injected with a median lethal dose (LD₅₀) of 1×10^{-2} TCID/ml (TCID: median tissue culture infective dose) of LF-89-like isolate provided by ADL Diagnostics Company. The experiment was conducted 43 days after the *P. salmonis* injection of Trojans.

The LD₅₀ used in Trojans was previously determined on 800 immunized fish with the vaccine, which were equally distributed in four treatments and two tanks of 1000 L per treatment. Treatment 1 involved injection with 1×10^{-2} TCID/ml, treatment 2 involved injection with 1×10^{-3} TCID/ml, treatment 3 involved injection with 1×10^{-4} TCID/ml, and treatment 4 involved injection with Phosphate-Buffered Saline (PBS). Fish were monitored daily for 30 days, and mortalities were recorded.

Challenge with EM-90-like and coinfection with sea lice (Trial 2). A total of 442 individually pit-tagged adult fish were provided in 2019 by the company Salmones Camanchaca and transferred to the experimental station of the Aquadvice company for the evaluation of the efficacy vaccine using a cohabitation challenge (Table 1). In total, 170 of the fish had been previously immunized with the vaccine using the normal production schedule and were used as vaccinated fish ($1,274 \pm 318$ g), 146 had been previously injected with Phosphate-Buffered Saline (PBS) and were used as unvaccinated fish ($1,260 \pm 345$ g), while the remaining fish were used as Trojan shedders ($1,311 \pm 346$ g).

Vaccinated and unvaccinated fish were distributed in three tanks of 11 m³: two tanks for the cohabitation challenges and one tank for the control without infection. All fish were acclimatized to the experimental conditions (salinity of 32‰ and a temperature of 15 ± 1 °C) and tanks for at least 15 days prior to the challenge. Further, a health check by RT-PCR was performed to verify that the fish

were free of viral (ISAV and IPNV) and bacterial pathogens (*Vibrio* sp., *Flavobacterium* sp., *P. salmonis*, and *Renibacterium salmoninarum*). The cohabitation tanks were challenged by adding Trojan shedders (table 1) which had been previously anesthetized with AQUI-S and injected with a median lethal dose (LD₅₀) of $1 \times 10^{-3.5}$ TCID/ml of EM-90-like isolate provided by Fraunhofer, Chile. After seven days of the Trojan fish being challenged with *P. salmonis*, all fish (cohabitant, Trojan and control) were infested with copepodids of *C. rogercresseyi*. The coinfection procedure was established based on our previous studies (Araya et al., 2012; Lhorente et al., 2014), but now a very low infection rate was applied to mimic the natural infection rates normally seen in field conditions (Bravo et al., 2010). Infections with sea lice were performed by adding 20 copepodites per fish to each control and coinfection tank. Copepodites were collected from egg-bearing females reared in the laboratory and confirmed as pathogen-free (*P. salmonis*, *R. salmoninarum*, IPNV, and ISAV) by RT-PCR diagnosis. After the addition of parasites, water flow was stopped for a period of 8 h, and tanks were covered to decrease light intensity, which favors the successful settlement of sea lice on fish (Araya et al., 2012). Parasite counting was performed a week after the infestation in a sample of nine fish per tank. The challenge lasted 60 days after the Trojans' infection with *P. salmonis*.

The LD₅₀ used in Trojans was previously determined on 330 immunized fish with the vaccine, which were equally distributed in five treatments and two tanks of 720 L per treatment. Treatment 1 involved injection with $1 \times 10^{-1.5}$ TCID/ml, treatment 2 involved injection with $1 \times 10^{-2.5}$ TCID/ml, treatment 3 involved injection with $1 \times 10^{-3.5}$ TCID/ml, treatment 4 involved injection with $1 \times 10^{-4.5}$ TCID/ml, and treatment 5 involved injection with Phosphate-Buffered Saline (PBS). Fish were monitored daily for 30 days, and mortalities were recorded.

Necropsy analysis. Macroscopic lesions from 10 controls and cohabitant fish in each trial were analyzed. Two different veterinarians who were blinded to the treatments studied fresh samples from trials 1 or 2. In the challenge with LF-89-like, macroscopic lesions were evaluated at 21 days post-infection in the liver where vacuolar degeneration, hepatitis and hepatocyte atrophy were described according to their presence or absence. Further, 47 vaccinated and unvaccinated fish from cohabitation and control tanks were analyzed by immunohistochemistry to detect the presence or absence of *P. salmonis* in the liver at 21 days after challenges and at the end of the experiment. In the challenge with EM-90-like, clinical signs were evaluated at the end of the challenges; the analysis included presence or absence of nodules in the liver, congestive liver, and hepatomegaly.

ELISA. An indirect Enzyme-Linked Immunosorbent Assay (ELISA) was performed in serum samples only from the first trial—the fish challenged with LF-89-like isolate. Secretion levels of total immunoglobulin (Igs), antigen-specific immunoglobulins against *P. salmonis* (spIgs), tumor necrosis factor-alpha (TNFα) and interferon-gamma (IFNγ) were measured following the protocol of Morales-Lange *et al.* (Morales-Lange et al., 2018). Briefly, the total protein concentration of each sample was first determined by the BCA (Bicinchoninic acid) method (Pierce, Thermo Fisher, Waltham, USA) according to the supplier's instructions. Then, each sample was diluted in carbonate buffer (60 mM NaHCO₃, pH 9.6), seeded in duplicate at 50 ng μL⁻¹ (100 μL) in a Maxisorp plate (Nunc, Thermo Fisher Scientific, Waltham, USA) and incubated overnight at 4 °C. After that, the plates were blocked with 200 μL per well of 1% Bovine Serum Albumin (BSA) for 2 h at 37 °C, and later the primary antibodies (Supplementary table and figure 1) were incubated for 90 min at 37 °C. Next, a secondary antibody—HRP (Thermo Fisher)—was incubated for 60 min at 37 °C in a 1:7000 dilution. Finally, 100 μL per well of chromagen substrate 3,3',5,5'-tetramethylbenzidine (TMB) single solution (Invitrogen, California, USA) was added and incubated for 30 min at room temperature. The reaction was stopped with 50 μL of 1 N sulfuric acid and read at 450 nm on a VERSAmax microplate reader (Molecular Device, California, USA). For the detection of spIg, 50 ng μL⁻¹ of total protein extract from

P. salmonis (Carril et al., 2017) were seeded per well in a Maxisorp plate (diluted in 100 µL of carbonate buffer) and incubated overnight at 4 °C. After blocking with 1% BSA (200 µL per well), each fish serum sample was incubated in duplicate at a total Igs concentration of 50 ng µL⁻¹ for 90 min at 37 °C. After that, the ELISA protocol described above was followed.

Statistical analysis. The mortality was registered in all individuals, and data were represented using Kaplan–Meier survival curves (Kaplan and Meier, 1958). The protection elicited by vaccines was determined by comparing the percentage of survival of vaccinated and unvaccinated groups using a Log-rank test. Further, the relative proportion survival (RPS) was calculated as

$$RPS (\%) = \left(1 - \frac{A}{B}\right) * 100$$

where A and B are the mortalities at the end of challenges in vaccinated and unvaccinated fish, respectively.

Additionally, differences in the clinical signs of *P. salmonis* infection between different treatments were analyzed using a non-parametric Chi-square test. Finally, significant differences in ELISA tests were compared using the Student's two-tailed t-test, $p < 0.05$. All statistical analyses were performed using R Core Team (RStudio, Vienna, Austria). Graphs were designed with GraphPad Prism 8.0 software (GraphPad Software, CA, USA).

3 Results

Vaccine efficacy against LF-89-like isolate

As we expected, the cohabitation challenge with the LF-89-like isolate of *P. salmonis* resulted in high mortality in the cohabiting fish and no mortality in the non-infected control fish. However, we found no evidence that the evaluated vaccine generated an effective protection against this strain. The vaccine delayed mortalities by two days (H^U : 34 dpi and H^{VP} : 36 dpi), but unvaccinated fish and those vaccinated showed similar survival during and at the end of the challenges (H^{VP} : 56.7% and H^U : 60.3%, Figure 1A). The survival test did not reveal significant differences between vaccinated and unvaccinated treatments ($p = 0.28$).

Dead fish and large numbers of vaccinated and unvaccinated live fish at the end of the challenge showed multiple hemorrhagic ulcers on the skin typical of a severe *P. salmonis* infection. Infection with *P. salmonis* was also evident in both vaccinated and unvaccinated fish in the liver at the end of the challenge, but not at 21 days after infection (Figure 2). On the other hand, vaccination increased the presence of hepatocyte atrophy in comparison with unvaccinated fish in the control treatment at 21 days post-infection (Table 2). A similar trend was observed in the cohabitant fish, but without significant differences (Table 2). The health status of fish was evaluated again against most common salmon diseases, revealing the appearance of secondary infections of *Piscine orthoreovirus* (Supplementary Figure 3) and *Tenacibaculum dicentrarchi* in some fish.

The ELISA results in serum samples of *S. salar* showed a significant increase of total Igs at 21 days post-infection (Figure 3A) in the control group of vaccinated fish (C^{VP}). However, at the same sampling time, cohabiting fish (unvaccinated and vaccinated) showed a decrease in total Igs levels. This trend was reversed at 41 dpi, since both groups (H^U and H^{VP}) significantly increased their levels of total Igs. On the other hand, regarding specific immunoglobulins against *P. salmonis* (Figure 3B), an increase was detected in C^{VP} before the challenge with *P. salmonis*. Nevertheless, after 41 days post-infection,

211 H^{VP} group showed less availability of splgs against *P. salmonis* than the other groups. Finally, the
 212 evaluation of TNF α and IFN γ secretion did not show significant changes between treatments (Figure
 213 3C-D).

214 **Vaccine efficacy against EM-90-like isolate with low sea lice coinfection**

215 In the second trial, adult fish were coinfecting with sea lice to mimic natural conditions in the field.
 216 Seven days after sea lice infestation, the prevalence of sea lice was 100% in treatment and control
 217 tanks, with no significant differences in the abundance of the parasites between tanks (Tank 1 = 10.4
 218 $\pm$ 4.0; Tank 2 = 11.7 $\pm$ 3.0; control tank = 9.7 $\pm$ 6.6). In cohabitant fish, the vaccine was not able to
 219 protect Atlantic salmon against the EM-90-like strain (H^{VP}: 60.2% and H^U: 64.6%; Figure 1B; p =
 220 0.58) during a very low-level sea lice infection. However, a small protective effect was observed; for
 221 example, steady mortality started three days later for vaccinated fish compared with unvaccinated fish
 222 (H^{VP}: 48 dpi and H^U: 45 dpi). The control tank infected only with sea lice presented very low
 223 mortalities, with one fish dead of the unvaccinated fish (C^U) and two dead of the vaccinated fish (C^{VP}).

224 Vaccinated and unvaccinated dead fish showed hemorrhagic ulcers on the skin typical of a severe *P.*
 225 *salmonis* infection. Further, when we compared cohabitant and control fish at the end of the challenges,
 226 infection with *P. salmonis* was evident in the cohabitant fish in terms of the three evaluated clinical
 227 signs: nodules in liver, congestive liver and hepatomegaly (Table 3). However, we did not find
 228 differences between vaccinated and unvaccinated fish in cohabitant fish (Table 3). For instance, in the
 229 cohabitant treatment, nine unvaccinated fish presented a congestive liver, compared to 10 vaccinated
 230 fish with that condition. Similar patterns were found for nodules in the liver and hepatomegaly.

231 **4 Discussion**

232 Vaccination is one of the most relevant strategies to prevent and control diseases in aquaculture (Assefa
 233 and Abunna, 2018). However, vaccines have failed to control and prevent Piscirickettsiosis, for reasons
 234 that remain elusive (Adams, 2019; Alvarez et al., 2016; Cabello and Godfrey, 2019; Maissey et al.,
 235 2017). This manuscript evaluated whether the heterogeneity of *P. salmonis* could explain the low
 236 vaccine efficacy of a commercial vaccine whose active principle is a bacterin developed using the *P.*
 237 *salmonis* AL 10005 strain. To do that, we evaluated the vaccine efficacy using the two most prevalent
 238 and ubiquitous isolates of *P. salmonis* in Chile. Challenges were designed to mimic the natural
 239 condition of infection; thus, LF-89-like was evaluated with post-smolt fish in a single infection of *P.*
 240 *salmonis*, and EM-90-like was evaluated with adult fish in a challenge that included a very low
 241 coinfection pressure with the sea louse *C. rogercresseyi*. Thus, in this study, we found no evidence that
 242 the vaccine developed with the *P. salmonis* AL 10005 strain confers protection against LF-89-like or
 243 EM-90-like in Atlantic salmon.

244 The absent or low level of protection provided by vaccines against Piscirickettsia could be related to
 245 the selection of an incorrect model for the evaluation of protection in vaccination trials, which may
 246 lead to the overestimation of the real protective value of vaccines in the field. For example, the route
 247 of infection has been proposed as a relevant factor for defining the performance of a vaccine. Here, we
 248 selected a cohabitation model of challenges, because cohabitation challenges best mimic the natural
 249 infection route (Nordmo, 1997). On the other hand, several studies evaluating vaccine efficacy against
 250 *P. salmonis* have been performed by intraperitoneal injection (Kuzyk et al., 2001; Salonijs et al., 2005;
 251 Tobar et al., 2011; Wilhelm et al., 2006). Intraperitoneal injection is preferred because it is a
 252 synchronized and effective infection route that shortens the time to produce disease symptoms,
 253 decreasing the cost of trials (Cardella and Eimers, 1990; Meza et al., 2019). Vaccine protection efficacy

has been found to be affected by the route of infection for furunculosis (Midtlyng, 2005) but not for Piscirickettsiosis in Atlantic salmon (18).

On the other hand, coinfection with other pathogens such as sea lice is usually not considered in the evaluation of *P. salmonis* vaccine efficacy in laboratory-controlled conditions. We consider that this overestimates the true ability of vaccines to control Piscirickettsiosis for three reasons: first, sea lice are highly prevalent in the ocean; second, the long culture times in the sea ensure that fish will be infected not once only but several times by this pathogen; third, it has been shown that sea lice can override the protective effects of vaccination (Figueroa et al 2017). We observed no clinical sign associated with *P. salmonis* in the control tank, and mortality was significantly lower in the control tanks (less than 2–%; 3 of 137 fish) than in the cohabitating plus coinfection treatment (36–40%). Because we did not observe differences in mortality or clinical signs between vaccinated and unvaccinated adult fish in the cohabitating treatment, we predict that the evaluated vaccine will not protect fish in the field.

The immune mechanisms involved in vaccine protection against *P. salmonis* are poorly understood. In this research, the vaccine was able to induce an increase of sPIgs in vaccinated fish. However, this occurred before the challenge with *P. salmonis*. After the challenge, cohabitating fish showed only increases in total Igs (41 dpi) and even a decrease of sPIgs against *P. salmonis* to 41 dpi, perhaps due to B cell depletion. Apparently, the vaccine is not able to activate components of acquired immunity such as specific antibodies or cytokines associated with Th1 profiles (TNF α and IFN γ) once fish face *P. salmonis* infection, perhaps because *P. salmonis* is an intracellular pathogen. This suggests that the vaccine could act as an immunostimulant for the adaptive response at early time points, but not as a vaccine that induces future specific secondary responses. It has already been reported that vaccines may induce weaker or shorter-lived immunity in fish, mainly due to the low immunogenicity of the antigens used or because they cannot modulate the antigen presentation processes effectively during the different stages of immunity (Rozas-Serri et al., 2019). Therefore, the protective mechanism that Piscirickettsia vaccines might have in the field (Happold et al., 2020) needs to be clarified.

In Chile, the Agricultural and Livestock Service of Chile (SAG) authorized *P. salmonis* vaccines that meet a minimum protection of $\geq 70\%$ RPS to be marketed. However, there is little evidence of their effectiveness under field conditions (Happold et al., 2020). In this study, the minimum protection of RPS $\geq 70\%$ was not reproduced either against *P. salmonis* LF-89 strain or in the EM-90 strain. Unfortunately, neither the pharmaceutical companies nor the SAG (Agricultural and Livestock Service) publicly release the efficacy studies that authorize the marketing of vaccines in Chile. This prevented us from comparing our results with the studies carried out by pharmaceutical companies. Vaccine efficacy studies must be public and must consider both the genetic heterogeneity of the host and the pathogen's heterogeneity. In fact, we do not know if the most vulnerable groups of populations have been included when the efficacy of the Piscirickettsiosis vaccine was evaluated by the SAG as recommended by the World Organization for Animal Health (OIE) or if pathogen heterogeneity was considered.

5 Data Availability Statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation, to any qualified researcher.

6 Conflicts of Interest

296 We declare that J.A.G., L.M., and P.C. provided genetic and immunological services to different
297 salmon companies in Chile during the execution of this experiment. G.S and C.S. were employed in
298 Salmones Camanchaca during the execution of this research. C.F., D.T., B.M-L, and B.D. declare no
299 competing financial interest.

300 7 Author Contributions

301 J.A.G., C.S., C.F., G.S. conceived and designed the study with the help of PC and B.D. C.F., G.S.,
302 C.S., and J.A.G. performed the experiments. C.F. and D.T. performed the data analysis. B.M. and L.M
303 performed the analysis of the Immunological data. D.T. and J.A.G. wrote the paper with the help of all
304 authors.

305 8 Funding

306 This research study was funded by CONICYT-Chile through the project FONDECYT N°1140772
307 awarded to J.A.G and P.C. Furthermore, J.A.G was supported by the Cooperative Research Program
308 Fellowships of OECD - PCI 2015-CONICYT. C.F. was supported by PUCV and CONICYT-Chile
309 through a Postdoctoral fellowship (Proyecto VRIEA-PUCV Postdoctorado and FONDECYT
310 N°3170744). D.T. was supported by CONICYT-Chile through a Postdoctoral fellowship (Becas-Chile
311 N° 74170029). B.M-L was supported by the Postdoctoral program from the National Research and
312 Development Agency of Chile (ANID-Chile 74200139).

313 9 Acknowledgments

314 We wish to thank all of the staff from the salmon selective breeding program at Salmones Camanchaca,
315 with special thanks to Darwin Muñoz, Sonia Velazquez and Sergio Navarro for their professional
316 support and collaboration in the experimental work. We would like to thank Salmones Camanchaca
317 for providing fish, materials and logistics to perform this study. We would like to thank the staff of
318 Neosalmon and Aquadvice for their valuable contribution to the development of experiments.

319 10 References

- 320 Adams, A., 2019. Progress, challenges and opportunities in fish vaccine development. *Fish Shellfish*
321 *Immunol* 90, 210-214.
- 322 Alvarez, C.A., Gomez, F.A., Mercado, L., Ramirez, R., Marshall, S.H., 2016. *Piscirickettsia salmonis*
323 *Imbalances the Innate Immune Response to Succeed in a Productive Infection in a Salmonid Cell*
324 *Line Model. PloS one* 11, e0163943.
- 325 Araya, A., Mancilla, M., Lhorente, J.P., Neira, R., Gallardo, J.A., 2012. Experimental challenges of
326 Atlantic salmon *Salmo salar* with incremental levels of copepodids of sea louse *Caligus*
327 *rogercresseyi*: effects on infestation and early development. *Aquaculture Research* 43, 1904-1908.
- 328 Assefa, A., Abunna, F., 2018. Maintenance of Fish Health in Aquaculture: Review of
329 Epidemiological Approaches for Prevention and Control of Infectious Disease of Fish. *Veterinary*
330 *medicine international* 2018, 5432497.
- 331 Bohle, H., Henríquez, P., Grothusen, H., Navas, E., Sandoval, A., Bustamante, F., Bustos, P.,
332 Mancilla, M., 2014. Comparative Genome Analysis of Two Isolates of the Fish Pathogen
333 *Piscirickettsia salmonis* from Different Hosts Reveals Major Differences in Virulence-Associated
334 Secretion Systems. *GenomeA* 2.

- 335 Bravo, S., Treasurer, J., Sepulveda, M., Lagos, C., 2010. Effectiveness of hydrogen peroxide in the
336 control of *Caligus rogercresseyi* in Chile and implications for sea louse management. *Aquaculture*
337 303, 22-27.
- 338 Brocklebank, J., Ebelyn, T., Speare, D.J., Armstrong, R., 1993. Rickettsial septicemia in farmed
339 Atlantic and chinook salmon in British Columbia: Clinical presentation and experimental
340 transmission. *Can Vet J* 34, 745 - 748.
- 341 Cabello, F.C., Godfrey, H.P., 2019. Salmon aquaculture, *Piscirickettsia salmonis* virulence, and One
342 Health: Dealing with harmful synergies between heavy antimicrobial use and piscine and human
343 health. *Aquaculture* 507, 451-456.
- 344 Cardella, M.A., Eimers, M.E., 1990. Safety and Potency Testing of Federally Licensed Fish
345 Bacterins. *Journal of aquatic animal health* 2, 49-55.
- 346 Carril, G., Gómez, F., Marshall, S., 2017. Expression of flagellin and key regulatory flagellar genes
347 in the non-motile bacterium *Piscirickettsia salmonis*. *Dis Aquat Org.* 123, 29-43.
- 348 Figueroa, C., Bustos, P., Torrealba, D., Dixon, B., Soto, C., Conejeros, P., Gallardo, J.A., 2017.
349 Coinfection takes its toll: Sea lice override the protective effects of vaccination against a bacterial
350 pathogen in Atlantic salmon. *Scientific reports* 7, 17817.
- 351 Figueroa, C., Veloso, P., Spin, L., Dixon, B., Torrealba, D., Soto, C., Conejeros, P., Gallardo, J.A.,
352 2020 accepted. Host genetic variation explains reduced protection of commercial vaccines against
353 *Piscirickettsia salmonis* in Atlantic salmon. *Scientific Report*.
- 354 Grant, A.N., Brown, A.G., Cox, D.I., Birkbeck, T.H., Griffen, A.A., 1996. Rickettsia-like organism
355 in farmed salmon. *Veterinary Record* 138.
- 356 Happold, J., Sadler, R., Meyer, A., Hillman, A., Cowled, B., Mackenzie, C., Gallardo Lagno, A.L.,
357 Cameron, A., 2020. Effectiveness of vaccination for the control of salmonid rickettsial septicemia in
358 commercial salmon and trout farms in Chile. *Aquaculture* 520, 734968.
- 359 Jakob, E., Stryhn, H., Yu, J., Medina, M.H., Rees, E.E., Sanchez, J., St-Hilaire, S., 2014.
360 Epidemiology of Piscirickettsiosis on selected Atlantic salmon (*Salmo salar*) and rainbow trout
361 (*Oncorhynchus mykiss*) salt water aquaculture farms in Chile. *Aquaculture* 433, 288-294.
- 362 Kaplan, E.L., Meier, P., 1958. Nonparametric Estimation from Incomplete Observations. *Journal of*
363 *the American Statistical Association* 53, 457-481.
- 364 Kuzyk, M., Burian, J., Machander, D., Dolhaine, D., Cameron, S., Thornton, J., Kay, W., 2001. An
365 efficacious recombinant subunit vaccine against the salmonid rickettsial pathogen *Piscirickettsia*
366 *salmonis*. *Vaccine* 19, 2337-2344.
- 367 Leal, J., Woywood, D., 2007. Piscirickettsiosis en Chile: Avances y perspectivas para su control.
368 *Salmonciencia* 2, 34-42.
- 369 Lhorente, J.P., Gallardo, J.A., Villanueva, B., Carabano, M.J., Neira, R., 2014. Disease resistance in
370 Atlantic salmon (*Salmo salar*): coinfection of the intracellular bacterial pathogen *Piscirickettsia*
371 *salmonis* and the sea louse *Caligus rogercresseyi*. *PloS one* 9, e95397.
- 372 Maisey, K., Montero, R., Christodoulides, M., 2017. Vaccines for piscirickettsiosis (salmonid
373 rickettsial septicemia, SRS): the Chile perspective. *Expert review of vaccines* 16, 215-228.
- 374 Meza, K., Inami, M., Dalum, A.S., Lund, H., Bjelland, A.M., Sorum, H., Lovoll, M., 2019.
375 Comparative evaluation of experimental challenge by intraperitoneal injection and cohabitation of

376 Atlantic salmon (*Salmo salar* L.) after vaccination against *Piscirickettsia salmonis* (EM90-like).
377 Journal of fish diseases 42, 1713-1730.

378 Midtlyng, P., 2005. Critical assessment of regulatory standards and tests for fish vaccines, in: PJ, M.
379 (Ed.), Progress in fish vaccinology, Developments of Biologicals

380 Millar, A.D., Tapia, P., Gomez, F.A., Marshall, S.H., Fuentes, D.E., Valdes, J.H., 2018. Draft
381 genomes and reference transcriptomes extend the coding potential of the fish pathogen *Piscirickettsia*
382 *salmonis*. Electronic Journal of Biotechnology 33, 36-38.

383 Morales-Lange, B., González-Aravena, M., Font, A., Guzmán, F., Mercado, L., 2018. Detection of
384 peroxiredoxin-like protein in Antarctic sea urchin (*Sterechinus neumayeri*) under heat stress and
385 induced with pathogen-associated molecular pattern from *Vibrio anguillarum*. Polar Biology 41,
386 2065-2073.

387 Nordmo, R., 1997. Strengths and weaknesses of different challenge methods. Developments in
388 Biological Standardization 90, 303-309.

389 Nourdin-Galindo, G., Sanchez, P., Molina, C.F., Espinoza-Rojas, D.A., Oliver, C., Ruiz, P., Vargas-
390 Chacoff, L., Carcamo, J.G., Figueroa, J.E., Mancilla, M., Maracaja-Coutinho, V., Yanez, A.J., 2017.
391 Comparative Pan-Genome Analysis of *Piscirickettsia salmonis* Reveals Genomic Divergences within
392 Genogroups. Frontiers in cellular and infection microbiology 7, 459.

393 Olsen, A.J., Melby, H., Speilberg, L., Evensen, O., Hastein, T., 1997. *Piscirickettsia salmonis*
394 infection in Atlantic salmon *Salmo salar* in Norway-epidemiological, pathological and
395 microbiological findings. 31, 35-48.

396 Otterlei, A., Brevik, O.J., Jensen, D., Duesund, H., Sommerset, I., Frost, P., Mendoza, J., McKenzie,
397 P., Nylund, A., Apablaza, P., 2016. Phenotypic and genetic characterization of *Piscirickettsia*
398 *salmonis* from Chilean and Canadian salmonids. BMC veterinary research 12, 55.

399 Rozas, M., Enriquez, R., 2014. *Piscirickettsiosis* and *Piscirickettsia salmonis* in fish: a review.
400 Journal of fish diseases 37, 163-188.

401 Rozas-Serri, M., Ildefonso, R., Pena, A., Enriquez, R., Barrientos, S., Maldonado, L., 2017.
402 Comparative pathogenesis of *piscirickettsiosis* in Atlantic salmon (*Salmo salar* L.) post-smolt
403 experimentally challenged with LF-89-like and EM-90-like *Piscirickettsia salmonis* isolates. Journal
404 of fish diseases 40, 1451-1472.

405 Rozas-Serri, M., Pena, A., Arriagada, G., Enriquez, R., Maldonado, L., 2018. Comparison of gene
406 expression in post-smolt Atlantic salmon challenged by LF-89-like and EM-90-like *Piscirickettsia*
407 *salmonis* isolates reveals differences in the immune response associated with pathogenicity. Journal
408 of fish diseases 41, 539-552.

409 Rozas-Serri, M., Pena, A., Maldonado, L., 2019. Gene expression associated with immune response
410 in Atlantic salmon head-kidney vaccinated with inactivated whole-cell bacterin of *Piscirickettsia*
411 *salmonis* and pathogenic isolates. Fish Shellfish Immunol 93, 789-795.

412 Saavedra, J., Hernandez, N., Osses, A., Castillo, A., Cancino, A., Grothusen, H., Navas, E.,
413 Henriquez, P., Bohle, H., Bustamante, F., Bustos, P., Mancilla, M., 2017. Prevalence, geographic
414 distribution and phenotypic differences of *Piscirickettsia salmonis* EM-90-like isolates. Journal of
415 fish diseases 40, 1055-1063.

416 Saloni, K., Siderakis, C., Mackinnon, A., Griffiths, S., 2005. Use of *Arthrobacter davidanieli* as a
417 live vaccine against *Renibacterium salmoninarum* and *Piscirickettsia salmonis* in salmonids. Progress
418 in Fish Vaccinology 121, 189-197.

419 SERNAPESCA, 2017. Informe Sanitario de Salmonicultura en Centros Marinos 2016. Valparaíso:
420 Servicio Nacional de Pesca y Acuicultura.

421 Tobar, J.A., Jerez, S., Caruffo, M., Bravo, C., Contreras, F., Bucarey, S.A., Harel, M., 2011. Oral
422 vaccination of Atlantic salmon (*Salmo salar*) against salmonid rickettsial septicaemia. Vaccine 29,
423 2336-2340.

424 Wilhelm, V., Miquel, A., Burzio, L.O., Roseblatt, M., Engel, E., Valenzuela, S., Parada, G.,
425 Valenzuela, P.D., 2006. A vaccine against the salmonid pathogen *Piscirickettsia salmonis* based on
426 recombinant proteins. Vaccine 24, 5083-5091.

427

428

429

430

431

432 11 Tables

433 **Table 1.** Number and proportion of Atlantic salmon used per group and treatment for the first and
 434 second trials. In the first trial, post-smolt fish were challenged with the LF-89-like isolate of *P.*
 435 *salmonis*, while in the second trial, adult fish were challenged with the EM-90-like isolate of *P. salmonis*
 436 and with the sea lice *C. rogercresseyi*.

Group	Treatments	First trial	Second trial
Cohabitant	Vaccinated with pentavalent (H ^{VP})	496	83
	Unvaccinated (H ^U)	355	96
	Total cohabitant (H)	851	179
	H ^U / H	42%	53%
Trojan	Total Trojans (T)	2903	126
	T / (H + T)	77%	41%
Control	Vaccinated with pentavalent (C ^{VP})	727	74
	Unvaccinated (C ^U)	506	63
	Total control (C)	1233	137
	Total fish (H+T+C)	4987	442

437

438

439

440

441

442

443 **Table 2.** Clinical signs in Atlantic salmon challenged with the LF-89-like isolate of *P. salmonis* at day 21 post-infection in cohabitant and
 444 control groups. Differences between vaccinated and unvaccinated fish were evaluated with a Chi-squared statistical test.

Group	Clinical signs	Treatment		Proportion		Chi-square test.	
		Presence of clinical signs	Unvaccinated fish	Vaccinated fish	Unvaccinated fish	Vaccinated fish	X^2 p -value
Cohabitant	Vacuolar degeneration	No	2	4	0.20	0.40	0.2381 0.6256
		Yes	8	6	0.80	0.60	
		Total	10	10			
	Hepatitis	No	9	9	0.90	0.90	0 1
		Yes	1	1	0.10	0.10	
		Total	10	10			
	Hepatocyte atrophy	No	8	4	0.80	0.40	1.875 0.1709
		Yes	2	6	0.20	0.60	
		Total	10	10			
Control	Vacuolar degeneration	No	1	3	0.10	0.30	0.3125 0.5762
		Yes	9	7	0.90	0.70	
		Total	10	10			
	Hepatitis	No	8	7	0.80	0.70	0 1
		Yes	2	3	0.20	0.30	
		Total	10	10			
	Hepatocyte atrophy	No	10	5	1.00	0.50	4.2667 <0.05 *
		Yes	0	5	0.00	0.50	
		Total	10	10			

Table 3. Clinical signs in Atlantic salmon challenged with the EM-90-like isolate of *P. salmonis* and infestation with *C. rogercresseyi* at day 47–51 post-infection in cohabitant and control groups. Differences between vaccinated and unvaccinated fish were evaluated with a Chi-squared statistical test.

Group	Clinical signs	Presence of clinical signs	Treatment		Proportion		Chi-square test.	
			Unvaccinated fish	Vaccinated fish	Unvaccinated fish	Vaccinated fish	X^2	p -value
Cohabitant	Nodules in liver	No	0	0	0	0	0	1
		Yes	10	10	1	1		
		Total	10	10				
	Congestive liver	No	1	0	0.1	0	0.0023	0.961
		Yes	9	10	0.9	1		
		Total	10	10				
	Hepatomegaly	No	0	0	0	0	0	1
		Yes	10	10	1	1		
		Total	10	10				
Control	Nodules in liver	No	10	10	1	1	0	1
		Yes	0	0	0	0		
		Total	10	10				
	Congestive liver	No	10	9	1	0.9	0	1
		Yes	0	1	0	0.1		
		Total	10	10				
	Hepatomegaly	No	10	9	1	0.9	0	1
		Yes	0	1	0	0.1		
		Total	10	10				

12 Figure legends

Figure 1. Survival curves. **(A)** Single infection of Atlantic salmon post-smolt with the *P. salmonis* LF-89-like strain. **(B)** Coinfection of Atlantic salmon adults with the *P. salmonis* EM-90-like strain and the sea louse *C. rogercresseyi*. Significant differences were obtained from the Log-rank test. Abbreviations: C^U : control unvaccinated; C^{VP} : control vaccinated with pentavalent; H^U : cohabitant unvaccinated; H^{VP} : cohabitant vaccinated with pentavalent; T: trojan.

Figure 2. Presence of LF-89-like isolate of *P. salmonis* (black arrows) in liver samples of Atlantic salmon. Piscirickettsiosis was detected in 11 out of 47 fish analyzed by immunohistochemistry — magnification 63X.

Figure 3. Secretion of total Igs (A), antigen specific Igs (B), tumor necrosis factor alpha ($TNF\alpha$) (C) and interferon gamma ($IFN\gamma$) (D) in serum samples from Atlantic salmon measured by ELISA after a challenge with *P. salmonis* in the first trial (single infection of the LF-89-like isolate). Data represent the mean $\pm$ SEM ($n = 10$). Significant differences compared to C^U by Student t-test two-tailed ($p < 0.05$). Abbreviations: C^U : control unvaccinated; C^{VP} : control vaccinated with pentavalent; H^U : cohabitant unvaccinated; H^{VP} : cohabitant vaccinated with pentavalent.